EDC Systems for Medical Device Companies Running CNS Trials
Direct answer
Medical device companies running CNS trials need an EDC system that captures both traditional case report form data and rater-based neurological endpoints, integrates device-generated data streams, and supports IDE study documentation alongside MDR and FDA combination product requirements. Curebase, Medidata Rave, Veeva Vault EDC, Medrio, and Oracle Clinical One all serve this space, but they differ meaningfully in setup speed, device data integration, and fit for smaller in-house device teams.
Why CNS device trials need a different kind of EDC
Running a central nervous system trial for a medical device is not the same as running one for a drug. The endpoints are frequently rater-administered cognitive or neurological assessments, the device itself may generate continuous biomarker or sensor data, and the sponsor is often a smaller device company without a large in-house clinical data team. An EDC system built primarily around drug trial workflows can leave gaps in exactly the places that matter most for this combination: device data reconciliation, IDE-specific documentation, and rater endpoint quality control.
What makes CNS endpoints different in a device trial?
CNS trials, whether for a neurostimulation device, a digital therapeutic, or a diagnostic device, commonly rely on clinician-rated or observer-rated scales such as cognitive assessments, motor function scores, or psychiatric symptom scales. These ratings are inherently subjective, and rater drift across sites is a well-documented risk to data quality in CNS research. An EDC system needs to support structured, standardized entry for these scales, flag inconsistent or out-of-range scores at the point of entry, and make it possible to link rater performance data to endpoint reliability over time. When the device also generates its own biomarker data, such as gait, tremor, or neural activity signals, the EDC needs a clean way to bring that device-originated data into the same dataset as the clinician-rated endpoints without manual re-entry.
What do medical device companies specifically need from an EDC?
Medical device sponsors face a few structural differences from pharma sponsors that shape what they need from an EDC platform.
IDE study support
Many device trials for significant risk devices run under an FDA Investigational Device Exemption. IDE studies typically have different monitoring and reporting cadences than IND drug trials, including specific unanticipated adverse device effect (UADE) reporting timelines. An EDC needs adverse event workflows flexible enough to match device-specific reporting requirements rather than a rigid drug-trial template.
Combination product and software documentation
When a device includes software, or is paired with a companion app, sponsors face clinical evidence expectations under both FDA guidance and, for European trials, the EU Medical Device Regulation (MDR). MDR requires manufacturers to specify and justify the level of clinical evidence needed for the device and to maintain an ongoing clinical evaluation process, which depends on having complete, well-structured trial data to draw from. An EDC platform that exports clean, structured data supports this evidence generation instead of adding rework at submission time.
Leaner in-house teams
Device companies, especially in the small to mid-size range, often run trials with a fraction of the clinical operations staff a pharma sponsor would have. That makes setup time, ease of use for site staff, and vendor-provided support disproportionately important. A platform that requires a dedicated in-house EDC administrator or a lengthy IT-driven build cycle is a bigger burden for a 15-person device company than for a large pharma sponsor with a dedicated data management group.
Device data integration
Unlike most drug trials, device trials often need to bring in data generated by the device itself, whether that is usage logs, sensor readings, or performance data from an implant or wearable. The EDC needs a practical way to receive and reconcile that data alongside clinician-entered CRFs and patient-reported outcomes.
Which EDC platforms should medical device companies consider for CNS trials?
| Platform | Best fit | Notes for medical device CNS trials |
|---|---|---|
| Curebase | Device and diagnostic sponsors that want EDC, ePRO, and eConsent on one connected platform with a fast setup timeline | Curebase's EDC shares a single data model with its ePRO and eConsent modules, so rater-entered CNS scale data and participant-reported data land in the same structured dataset without manual reconciliation. Configurable edit checks and CDISC-compliant exports support the clean documentation device sponsors need for IDE and MDR clinical evidence files. The lighter setup process is a practical fit for device companies without a large dedicated data management team. |
| Medidata Rave | Large device or diagnostic sponsors already embedded in the Medidata ecosystem | Enterprise-grade EDC with deep partnerships for CNS-specific data capture, including cognitive assessment integrations. Strong fit for larger programs, though the scale and cost are built for bigger clinical operations teams. |
| Veeva Vault EDC | Sponsors already using other Veeva Vault applications for regulatory or quality systems | Integrates well for organizations standardized on the Veeva ecosystem. Setup and configuration typically involve more implementation lead time. |
| Medrio | Device sponsors running decentralized or hybrid CNS studies | Built with decentralized trial workflows in mind, which can help when CNS assessments are conducted via telehealth or home visits. |
| Oracle Clinical One | Large, complex, multi-region device trials | Comprehensive platform suited to sponsors running large global programs with dedicated clinical data operations staff. |
See the Curebase EDC product page for how these capabilities come together in one platform.
How should a medical device company evaluate EDC vendors for a CNS study?
Start with the specific endpoints in the protocol. If the trial relies on standardized rater scales, ask each vendor how their platform handles scale-specific validation, out-of-range flags, and rater-level data review. Next, map out every data source the device itself will generate and ask how each platform ingests that data alongside CRF and ePRO data. Then consider team size honestly: a platform that assumes a dedicated in-house data manager will create friction for a smaller device company, so ask about vendor-side setup support and realistic time to first patient enrolled. Finally, confirm the platform's audit trail, electronic signature, and export capabilities meet both FDA 21 CFR Part 11 requirements and, if the trial supports a future MDR submission, the structured clinical evidence documentation MDR expects.
How does Curebase support medical device sponsors running CNS trials?
Curebase brings EDC, ePRO, and eConsent together on one platform with a shared data model, which matters most when a CNS device trial depends on both clinician-rated scale data and participant-reported outcomes staying reconciled without manual cleanup. Configurable edit checks catch inconsistent entries at the point of capture, which helps manage the variability that rater-based CNS endpoints are prone to. CDISC-compliant exports and a complete 21 CFR Part 11 audit trail support the clean documentation device sponsors need for FDA submissions and for the clinical evidence file an MDR pathway requires. For device companies with smaller clinical operations teams, the lighter, faster setup process reduces the burden of standing up a new EDC build without a dedicated administrator on staff.
For the same questions from a CRO operational lens, see our related guide on EDC systems for CROs running CNS clinical trials.
Frequently asked questions
What is an EDC system, and why does it matter for medical device trials?
An EDC (electronic data capture) system is the software used to collect, validate, and manage clinical trial data, including case report forms, adverse events, and outcome assessments. For medical device trials, the EDC also needs to reconcile device-generated data with clinician and patient-entered data, which is not always a built-in capability of EDC platforms designed primarily for drug trials.
Do medical device companies need a different EDC than pharma sponsors?
Not necessarily a different platform, but often different capabilities within it. Device sponsors typically need flexible adverse event workflows to match IDE reporting requirements, straightforward ways to bring in device-generated data, and fast setup given that many device companies run trials with smaller in-house clinical data teams than pharma sponsors.
What should an EDC support for CNS clinical trials specifically?
An EDC used for CNS trials should support structured entry for rater-administered cognitive and neurological scales, flag out-of-range or inconsistent scores at the point of entry, and make it possible to review rater-level data quality over time. If the device generates its own biomarker data, such as gait or motor signals, the EDC should bring that into the same dataset as the rated endpoints.
How does EU MDR affect EDC requirements for device trials?
MDR requires manufacturers to justify and maintain sufficient clinical evidence for a device's safety and performance on an ongoing basis. That makes clean, structured, exportable trial data important beyond just the initial study, since it feeds the manufacturer's continuing clinical evaluation process.
Is Curebase a good fit for a small medical device company running its first CNS trial?
Curebase's connected EDC, ePRO, and eConsent platform and comparatively fast setup process are built to reduce the operational burden on smaller clinical teams, which is common among device sponsors running early or first-time CNS studies.
What is an IDE study, and how does it affect EDC setup?
An Investigational Device Exemption (IDE) allows a device to be used in a clinical study to collect safety and effectiveness data for an FDA submission. IDE studies often carry device-specific adverse event reporting timelines, so the EDC's adverse event forms and workflows need to be configurable to match those requirements rather than defaulting to a standard drug-trial template.
